In today's Pharmaceutical Executive Daily, GSK enters an exclusive collaboration with Sino Biopharmaceutical's CTTQ ...
An exclusive China launch collaboration positions CTTQ to lead importation, distribution, hospital access, and promotion, while GSK retains marketing authorization and oversight of regulatory, quality ...
Tris Pharmaceutical’s founder and CEO Ketan Mehta spoke with Pharmaceutical Executive about the company’s history and how ...
Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...
White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...
Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...
TRuE-AD4 enrolled adults with 10%–20% BSA moderate atopic dermatitis and prior inadequate response, intolerance, or ...
Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in ...
FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...
FDA’s three-month extension was triggered by a major amendment after the agency requested additional information during priority review, necessitating more time to evaluate newly submitted materials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results